Revenue Of Leqembi (Preliminary Basis)

Biogen

06/02/2026 11:03

Feb 6 (Reuters) - Eisai Co Ltd 4523.T:

EISAI CO LTD: REVENUE OF LEQEMBI (PRELIMINARY BASIS)

EISAI CO LTD: GLOBAL REVENUE (PRE-AUDIT BASIS) OF ANTI-AMYLOID-BETA PROTOFIBRIL ANTIBODY LEQEMBI WAS 61.8 BILLION YEN FOR THE CUMULATIVE PERIOD OF Q3 OF FY2025

Source text: ID:nTSnf8673d

Further company coverage: 4523.T

 (Reporting by Tokyo Newsroom)

 ((+81345201189;))